Gyre Pharmaceuticals

Gyre Pharmaceuticals is a leading pharmaceutical manufacturing company dedicated to the research, development, production, and commercialization of innovative drugs. Focusing primarily on organ fibrosis diseases, Gyre Pharmaceuticals stands at the forefront of medical advancements, addressing critical unmet needs in global healthcare. As a holding subsidiary of Gyre Therapeutics, Inc. (NASDAQ: GYRE), Gyre Pharmaceuticals benefits from a strong foundation and a commitment to pioneering treatments. The company's dedication ensures the highest standards of quality and efficacy in its products, making a significant impact on patient lives worldwide.

Gyre Pharmaceuticals' flagship product, ETUARY® (Pirfenidone Capsule), exemplifies its commitment to innovation. As one of only two drugs approved for Idiopathic Pulmonary Fibrosis (IPF) treatment worldwide, ETUARY® has revolutionized the therapeutic landscape. Launched in China in 2014, it was the first innovative drug approved for IPF treatment in the country, marking a significant milestone in addressing this critical medical need. The company’s robust pipeline also includes F351 (Hydronidone), a key product candidate for liver fibrosis treatment, which has been granted Breakthrough Therapy designation by the CDE, reinforcing Gyre Pharmaceuticals' role as an innovator in the pharmaceutical industry.

With its headquarters in Beijing, China, Gyre Pharmaceuticals continues to expand its research and development efforts, striving to bring more groundbreaking treatments to market. The company’s integrated approach, from R&D to commercialization, ensures a seamless delivery of high-quality pharmaceutical products. Gyre Pharmaceuticals is dedicated to improving patient outcomes and transforming the treatment of organ fibrosis diseases globally. To further explore opportunities with Gyre Pharmaceuticals and discover how your business can benefit, we invite the company’s management to create a customized and exclusive company showcase and product listing on our platform.